Predictors of Success in Gout Treatment

REFERENCES

1. 1.↵
   1. Singh JA,
   2. Yang S,
   3. Saag KG

   . Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Administration gout cohort. J Rheumatol 2020;47:449–60.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Pisaniello HL,
   2. Lester S,
   3. Gonzalez-Chica D,
   4. Stocks N,
   5. Longo M,
   6. Sharplin G,
   7. et al.

   Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study. Arthritis Res Ther 2018;20:143.

   OpenUrl
3. 3.↵
   1. Rai SK,
   2. Avina-Zubieta JA,
   3. McCormick N,
   4. De Vera MA,
   5. Shojania K,
   6. Sayre EC

   . The rising prevalence and incidence of gout in British Columbia, Canada: population-based trends from 2000 to 2012. Semin Arthritis Rheum 2017;46:451–6.

   OpenUrl
4. 4.↵
   1. Bardin T,
   2. Bouee S,
   3. Clerson P,
   4. Chales G,
   5. Flipo R,
   6. Liote F,
   7. et al.

   Prevalence of gout in the adult population of France. Arthritis Care Res 2016;68:261–6.

   OpenUrl
5. 5.↵
   1. Singh JA

   . The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther 2014;16:R132.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Vaccher S,
   2. Kannangara DR,
   3. Baysari MT,
   4. Reath J,
   5. Zwar N,
   6. Williams KM,
   7. et al.

   Barriers to care in gout: from prescriber to patient. J Rheumatol 2016;43:144–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Yin R,
   2. Li L,
   3. Zhang G,
   4. Reath J,
   5. Zwar N,
   6. Williams K,
   7. et al.

   Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. BMJ Open 2018;8:e017542.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Ramsubeik K,
   2. Ramrattan LA,
   3. Kaeley GS,
   4. Singh JA

   . Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 2018;10:235–52.

   OpenUrl
9. 9.↵
   1. Gonzalez-Senac NM,
   2. Bailen R,
   3. Torres RJ,
   4. de Miguel E,
   5. Puig JG

   . Metabolic syndrome in primary gout. Nucleosides Nucleotides Nucleic Acids 2014;33:185–91.

   OpenUrl
10. 10.↵
    1. Doherty M,
    2. Jansen TL,
    3. Nuki G,
    4. Pascual E,
    5. Perez-Ruiz F,
    6. Punzi L,
    7. et al.

    Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765–70.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Kuehn BM

    . Chronic disease approaches needed to curb gout’s growing burden. JAMA 2018;319:1307–9.

    OpenUrl
12. 12.↵
    1. Stack AG,
    2. Johnson ME,
    3. Blak B,
    4. Klein A,
    5. Carpenter L,
    6. Morlock R,
    7. et al.

    Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open 2019;9:e031550.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Dalbeth N,
    2. House ME,
    3. Horne A,
    4. Te Karu L,
    5. Petrie K,
    6. McQueen F,
    7. et al.

    The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin Rheumatol 2013;32:247–51.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Scheepers LEJM,
    2. Burden AM,
    3. Arts ICW,
    4. Spaetgens B,
    5. Souverein P,
    6. de Vries F,
    7. et al.

    Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology 2018;57:1641–50.

    OpenUrl
15. 15.↵
    1. Jennings CG,
    2. Mackenzie IS,
    3. Flynn R,
    4. Ford I,
    5. Nuki G,
    6. De Caterina R,
    7. et al.

    Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum 2014;44:25–30.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Nuki G,
    2. Doherty M,
    3. Richette P

    . Current management of gout: practical messages from 2016 EULAR guidelines. Pol Arch Intern Med 2017;127:267–77.

    OpenUrl
17. 17.↵
    1. Briesacher BA,
    2. Andrade SE,
    3. Fouayzi H,
    4. Chan KA

    . Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437–43.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Bradley EH,
    2. McGraw SA,
    3. Curry L,
    4. Buckser A,
    5. King K,
    6. Kasl S,
    7. et al.

    Expanding the Andersen Model: the role of psychosocial factors in long-term care use. Health Serv Res 2002;37:1221–42.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Glasheen WP,
    2. Cordier T,
    3. Gumpina R,
    4. Haugh G,
    5. Davis J,
    6. Renda A

    . Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits 2019;12:188–97.

    OpenUrl
20. 20.↵
    1. Day RO,
    2. Frensham LJ,
    3. Nguyen AD,
    4. Baysari M,
    5. Aung E,
    6. Lau A,
    7. et al.

    Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. BMJ Open 2017;7: e017281.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Doherty M,
    2. Jenkins W,
    3. Richardson H,
    4. Sarmanova A,
    5. Abhishek A,
    6. Ashton D,
    7. et al.

    Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392:1403–12.

    OpenUrl
22. 22.↵
    1. Counsell AB,
    2. Nguyen AD,
    3. Baysari MT,
    4. Kannangara DRW,
    5. McLachlan AJ,
    6. Day RO

    . Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Fam Pract 2018;19:54.

    OpenUrl
23. 23.↵
    1. Mikuls TR,
    2. Cheetham TC,
    3. Levy GD,
    4. Rashid N,
    5. Kerimian A,
    6. Low KJ,
    7. et al.

    Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med 2019;132:354–61.

    OpenUrl